

GODAVARI DRUGS LIMITED

Regd. Off.:'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

14.11.2024

To, The Manger [Listing] The BSE Limited The Secretary, Listing Department Phirozejeejeebhoy Towers, Dalal Street, Fort, Mumbai- 400001 Scrip code: 530317

Dear Sirs/Madam,

Sub: Outcome of the Board Meeting of Godavari Drugs Limited (the Company) held on Thursday 14th November, 2024 Ref: Reg. 30 read with Reg. 33 of SEBI (LODR) Regulations, 2015

We wish to inform you that the Board of Directors of the Company at their meeting held on today, i.e. November 14, 2024 has, inter alia, transacted the following business:

 Considered and approved the un-audited Financial Results for the quarter and half year ended 30th September, 2024 with limited review report as recommended by the Audit Committee and reviewed by the Statutory Auditors.,

The Board Meeting Commenced at 03:00 P.M and concluded at 04:40 PM

A Copy of said results together with the limited review report is enclosed herewith for the Second quarter and half year ended September 30, 2024 are enclosed herewith.

These are also made available on the website of the company at www.godavaridrugs.com

This is for your information and records.

Thanking You, For Godavari Drugs Limited

Venkatesh Achanta Company Secretary & Compliance Officer Membership Number : A53326

GODAVARI DRUGS LIMITED

CIN: L24230TG1987PLC008015

Regd Office :" Mayfair" S,P. Road,, Secunderabad

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

SI	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
N		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	2608.79	3220.75	3954.25	5829.54	7496.13	15671.19
2	Other Income	0.94	76.51	0.35	77.45	45.56	61.75
3	Total Revenue from operations (1+2)	2609.73	3297.26	3954.60	5906.99	7541.69	15732.94
4	Expenses						
	(a) Cost of materials consumed	1697.53	2694.83	3035.42	4392.36	5679.76	12194.76
	Changes in inventories of finished goods & (b) work-in-progress	59.25	-354.06	40.27	-294.81	202.60	-113.67
	(c) Employee benefits expense	137.91	126.43	119.06	264.34	241.01	513.05
	(d) Depreciation & amortization expense	58.22	54.96	49.38	113.18	96.76	199.46
	(e) Finance Costs	107.98	143.52	129.81	251.50	240.79	491.50
	(f) Other Expenses	423.63	430.37	453.23	854.00	841.62	1746.62
	Total expenses	2484.52	3096.05	3827.17	5580.57	7302.54	15031.72
5	Profit before exceptional Items and tax (3-4)	125.21	201.21	127.43	326.42	239.15	701.22
6	Exceptional items						-9.04
7	Profit before Tax (5-6)	125.21	201.21	127.43	326.42	239.15	692.18
8	Tax expense	-16.35	-38.13	-41.85	-54.48	-72.53	-137.28
9	Net Profit for the period (7-8)	108.86	163.08	85.58	271.94	166.62	554.90
10	Other Comprehensive Income						-
	Items that will not be reclassified to profit or (i) loss						-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss		· · ·	-	-	-	
	Items that will be reclassified to profit or (iii) loss		-	-	-		
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-		-		-
	Total Other Comprehensive Income (Net of Ta	Strates-	-	-	-	-	
11		108.86	163.08	85.58	271.94	166.62	554.90
	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05
	Other Equity						3143.56
14	Earnings per share (of Rs. 10/- each) (not annualized)						
	(a) Basic	1.45	2.17	1.14	3.61	2.21	7.37
	(b) Diluted	1.45	2.17	1.14	3.61	2.21	7.37

1) The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 14th November, 2024.

 The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3) The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.

4) Corresponding figures in previsous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED MohitJaju Wholetime Director & CFO DIN: 03405414

DA

SEC'BA

Place: Secunderabad Date : 14.11.2024

GODAVARI DRUGS LIMITED

CIN NO.L24230TG1987PLC008016 Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

Statement of Assets and Liabilities

Particulars	Half Year ended 30.09.2024	(Rs. In Lakhs) Year ended 31.03.2024	
100570	(Unaudited)	(Audited)	
ASSETS			
1. Non-current assets	3425.18	2668.39	
(a) Property, Plant and Équipment	1844.15	1832.06	
(b) Capital work-in-progress	1044.13	1052.00	
(c) Investment Property			
(d) Goodwill			
(e) Other Intangible assets			
(f) Intangible assets under development			
(g) Biological Assets other than bearer plant			
(h) Financial Assets (i) Investments	0.01	0.01	
	0.01	0.01	
(ii) Trade Receivables			
(iii) Loans	148.71	126.72	
(iv)Other (to be specified)	140.71	120.12	
(i) Deferred tax assets (net)			
(j) Other non-current assets			
2.Current assets	0004.04	0005.04	
(a) Inventories	2021.64	2065.04	
(b) Financial Assets			
(i) Investments	4440.04	5040.00	
(ii) Trade Receivables	4448.84	5942.33	
(iii) Cash and cash equivalents	297.84	262.29	
(iv) Bank balances other than (iii) above	00.40	00.40	
(v) Loans	92.40	89.49	
(vi) Other (to be specified)	470.54	488.92	
(c) Loans			
(d) Other current assets			
Total Assets	12749.31	13475.25	
EQUITY AND LIABILITIES			
PAUTY			
EQUITY	753.05	753.05	
(a) Equity Share Capital	3415.50	3143.56	
(b) Other Equity	3415.50	3143.50	
LIABILITIES			
1. Non-current assets (a) Financial Liabilities			
	1979.01	1116.74	
(i) Borrowings (ii) Trade Payable	1070.01	1110.1	
(iii) Other financial liabilities (other than those		75.57	
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) 	91.01		
(iii) Other financial liabilities (other than those specified in item (b), to be specified)(b) Provisions	81.01		
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) 	81.01 186.33		
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 			
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 2. Current liabilities 			
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 2. Current liabilities (a) Financial Liabilities 	186.33	186.33	
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 2. Current liabilities (a) Financial Liabilities (b) Borrowings 	186.33 3903.99	186.33 4445.74	
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 2. Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade Payable 	186.33	186.33 4445.74	
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 2. Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade Payable (iii) Other financial liabilities (other than those 	186.33 3903.99 1651.98	186.33 4445.74 3162.72	
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 2. Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade Payable (iii) Other financial liabilities (other than those specified in item (c), 	186.33 3903.99 1651.98 717.67	186.33 4445.74 3162.72	
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 2. Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade Payable (iii) Other financial liabilities (other than those 	186.33 3903.99 1651.98	186.33 4445.74 3162.72	
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 2. Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade Payable (iii) Other financial liabilities (other than those specified in item (c), (b) Other current liabilities (c) Provisions 	186.33 3903.99 1651.98 717.67 6.29	186.33 4445.74 3162.72 476.00	
 (iii) Other financial liabilities (other than those specified in item (b), to be specified) (b) Provisions (c) Defferred Tax liabilities (net) (d) Other non-current liabilities 2. Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade Payable (iii) Other financial liabilities (other than those specified in item (c), (b) Other current liabilities 	186.33 3903.99 1651.98 717.67	4445.74 3162.72 476.00	

FOR GODAVARI DRUGS LIMITED

Place: Secunderabad Date : 14.11.2024 Mohit Jaju Wholetime Director & CFO DIN: 03405414

DR SEC'BAI ∢ 0

GODAVARI DRUGS LIMITED CIN NO.L24230TG1987PLC008016 Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

Particulars	Half Year ended 30.09.2024 (Unaudited)	Yeare ended 31.03.2024 (Audited)
A. Cash Flow from Operating Activities	4	
Profit before Depreciation, Interest and Tax	691.10	1,383.13
Less : Other Income considered separately	(77.45)	(61.75
Net	613.65	1,321.38
(Increase) / Decrease in Inventories	43.40	(79.49
(Increase) / Decrease in Receivables	1,493.49	(148.83
(Increase) / Decrease in Short term loans & Advances	(2.90)	(0.73
(Increase) / Decrease in Others	18.38	35.37
Increase / (Decrease) in Current Liabilities	(1,804.53)	815.33
Income Tax Paid	. (115.54)	(101.67
Total A	245.95	1,841.36
B. Cash Flow from Investing Activities		
(Increase)/Decrease in Fixed Assets	(882.06)	(1,320.14
(Increase)/Decrease in Non current assets	(21.99)	(82.54
Sale of retired fixed assets (scraoe)		18.77
Other Income	77.45	61.75
Total B	(826.60)	(1,322.16
C. Cash Flow from Financing Activities	4	
Increase/(Decrease) in Long Term Borrowings	862.27	(78.01
Increase/(Decrease) in Provisions	5.43	4.13
Interest paid	(251.50)	(491.49
Total C	616.20	(565.37
D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C]	35.55	(46.17
	262.29	308.46
Cash and cash equivalents at the beginning of the year		
Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the Period	297.84	262.29

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024

For GODAVARI DRUGS LIMITED

Mohit Jaju

Wholetime Director & CFO DIN: 03405414



Place: Secunderabad Date : 14.11.2024

Ayyadevara & Co. Chartered Accountants

1-2-386/A/1, Gagan Mahal Hyderabad - 500 029 Ph. +91-40-27632354, 27642952 e-mail sridevar@yahoo.co.in URL www.ayyadevara.com

Independent Auditor's Review Report on unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Board of Directors, Godavari Drugs Limited Secunderabad.

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter ended 30th September, 2024 (the statement), This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepare policies hance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co., Chartered Accountants FRN: 00278S

Ayyadevara Srinivas Proprietor Membership No.028803 Secunderabad, Date :14/11/2024. UDIN: 24028803BKHJHQ2737

